Anika Therapeutics Inc.
ANIK
Get informed when a big investor buys or sells
+ FollowMarket Cap$262.04M
Close$
$17.75
14.2% downside
Current Fair Value
14.2% downsideOvervalued by 14.2% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $262.04 Million |
|---|---|
| Enterprise Value | $246.94 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.76 |
| Beta | 0.21 |
| Outstanding Shares | 13,430,000 |
Return
| Return on Equity | -1.66% |
|---|---|
| Return on Assets | -1.24% |
| Return on Invested Capital | -0.85% |
Valuation & Multiples
| P/E Ratio | -72.65 |
|---|---|
| PEG | 39.63 |
| Price to Sales | 2.59 |
| Price to Book Ratio | 2.07 |
| Enterprise Value to Revenue | 2.05 |
| Enterprise Value to EBIT | -180.64 |
| Enterprise Value to Net Income | -109 |
| Total Debt to Enterprise | 0.09 |
| Debt to Equity | 0.17 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
July 29, 2026
EPS Estimate
$0.03
Average shareholder expectationRevenue Estimate
$29.21 M
Average shareholder expectationNext Earnings Call
Expected Date
November 4, 2026
EPS Estimate
$0.42
Average shareholder expectationRevenue Estimate
$29.44 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.03%▼ 91.25% |
|---|---|
| Total Invested | $82,473▼ 99.95% |
| Investors Holding | 4▼ 131.00% |
ESG Score
No data
About Anika Therapeutics Inc.
CEO: Joseph Darling